Spots Global Cancer Trial Database for solid tumor, unspecified, adult
Every month we try and update this database with for solid tumor, unspecified, adult cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Gustave Roussy Cancer Profiling | NCT04932525 | Solid Tumor, Un... | Biopsy | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | NCT04252339 | Solid Tumor, Un... | RLY-1971 | 18 Years - | Hoffmann-La Roche | |
| Gustave Roussy Cancer Profiling | NCT04932525 | Solid Tumor, Un... | Biopsy | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | NCT03628677 | Solid Tumor, Un... | Domvanalimab Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| The Safety and Dosimetry Study of 177Lu-LNC1004 Injection | NCT05723640 | Solid Tumor, Un... | 177Lu-LNC1004 I... 177Lu-LNC1004 I... 177Lu-LNC1004 I... 177Lu-LNC1004 I... | 21 Years - | Yantai LNC Biotechnology Singapore PTE. LTD. | |
| The Safety and Dosimetry Study of 177Lu-LNC1004 Injection | NCT05723640 | Solid Tumor, Un... | 177Lu-LNC1004 I... 177Lu-LNC1004 I... 177Lu-LNC1004 I... 177Lu-LNC1004 I... | 21 Years - | Yantai LNC Biotechnology Singapore PTE. LTD. | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| Psychotherapy Intervention for Latinos With Advanced Cancer | NCT04015609 | Solid Tumor Solid Tumor, Ad... Solid Tumor, Un... | Meaning Centere... Functional Asse... Meaning Centere... Pre-assessment ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | NCT04252339 | Solid Tumor, Un... | RLY-1971 | 18 Years - | Hoffmann-La Roche | |
| RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | NCT04252339 | Solid Tumor, Un... | RLY-1971 | 18 Years - | Hoffmann-La Roche | |
| Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values | NCT04942717 | Solid Tumor Solid Tumor, Ad... Solid Tumor, Un... | CONVO intervent... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| Gustave Roussy Cancer Profiling | NCT04932525 | Solid Tumor, Un... | Biopsy | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment | NCT05695638 | Solid Tumor, Un... Haematological ... | 18 Years - | Aalborg University Hospital | ||
| Psychotherapy Intervention for Latinos With Adv Cancer | NCT04537936 | Solid Tumor Solid Tumor, Ad... Solid Tumor, Un... | Meaning Centere... Functional Asse... Meaning Centere... Pre-assessment ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors | NCT04643418 | Solid Tumor, Un... | MPB-1734 | 18 Years - | MegaPro Biomedical Co. Ltd. | |
| Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | NCT04100694 | NRG1 Fusion Pancreatic Canc... Non Small Cell ... Solid Tumor, Un... Prostate Cancer Head and Neck C... Colorectal Canc... Breast Cancer Cholangiocarcin... Renal Cell Carc... Unknown Primary... | MCLA-128 | 18 Years - | Merus N.V. | |
| Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | NCT03318445 | Solid Tumor, Un... | Rucaparib Irinotecan | 18 Years - | University of California, San Francisco | |
| Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors | NCT04169321 | Solid Tumor, Un... Lymphoma | Single Arm | 18 Years - | Cytosite Biopharma Inc. | |
| Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment | NCT05695638 | Solid Tumor, Un... Haematological ... | 18 Years - | Aalborg University Hospital | ||
| Psychotherapy Intervention for Latinos With Adv Cancer | NCT04537936 | Solid Tumor Solid Tumor, Ad... Solid Tumor, Un... | Meaning Centere... Functional Asse... Meaning Centere... Pre-assessment ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment | NCT05695638 | Solid Tumor, Un... Haematological ... | 18 Years - | Aalborg University Hospital | ||
| An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | NCT04443088 | Cancer Solid Tumor, Ad... Cancer Metastat... Solid Carcinoma Solid Tumor, Un... Tumor, Solid | INV-1120 Pembrolizumab | 18 Years - | Shenzhen Ionova Life Sciences Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
